A decade of FRAX: how has it changed the management of osteoporosis?

[1]  T. Peters,et al.  Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial , 2019, Osteoporosis International.

[2]  C. Cooper,et al.  Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures , 2019, Osteoporosis International.

[3]  J. Kanis,et al.  Fracture prediction from self-reported falls in routine clinical practice: a registry-based cohort study , 2019, Osteoporosis International.

[4]  F. Rutters,et al.  The Effect of a Screening and Treatment Program for the Prevention of Fractures in Older Women: A Randomized Pragmatic Trial , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[5]  J. Kanis,et al.  Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry‐Based Cohort Study , 2019, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  J. Kanis,et al.  The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. , 2019, Kidney international.

[7]  A. Grauer,et al.  Risk of subsequent fracture after prior fracture among older women , 2018, Osteoporosis International.

[8]  J. Kanis,et al.  Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  J. Kanis,et al.  Characteristics of recurrent fractures , 2018, Osteoporosis International.

[10]  R. Rizzoli,et al.  ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis , 2018, The Journal of clinical endocrinology and metabolism.

[11]  C. Cooper,et al.  The Cost‐Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  T. Peters,et al.  Management of Patients With High Baseline Hip Fracture Risk by FRAX Reduces Hip Fractures—A Post Hoc Analysis of the SCOOP Study , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  C. Cooper,et al.  Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial , 2017, The Lancet.

[14]  P. Geusens,et al.  Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.

[15]  C. Cooper,et al.  Service level predictors of bone treatment recommendations after a fragility fracture: Baseline findings from the first UK patient level Fracture Liaison Service Audit , 2018 .

[16]  J. Kanis,et al.  FRAX-based intervention and assessment thresholds in seven Latin American countries , 2018, Osteoporosis International.

[17]  M. Bech,et al.  Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study , 2018, Osteoporosis International.

[18]  A. Grauer,et al.  Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.

[19]  J. Kanis,et al.  FRAX- vs. T-score-based intervention thresholds for osteoporosis , 2017, Osteoporosis International.

[20]  Anders Odén,et al.  Overview of Fracture Prediction Tools. , 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[21]  E. Skovlund,et al.  Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway , 2017, Osteoporosis International.

[22]  C. Cooper,et al.  UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.

[23]  D. Dempster,et al.  Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  J. Kanis,et al.  FRAX Update. , 2017, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[25]  V. Gudnason,et al.  Imminent risk of fracture after fracture , 2017, Osteoporosis International.

[26]  C. Cooper,et al.  A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.

[27]  R. Neer,et al.  Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[28]  J. Kanis,et al.  Adjusting Hip Fracture Probability in Men and Women Using Hip Axis Length: the Manitoba Bone Density Database. , 2016, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[29]  Jacques P. Brown,et al.  A Meta‐Analysis of Trabecular Bone Score in Fracture Risk Prediction and Its Relationship to FRAX , 2016, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  G. Kyriakos,et al.  Impact of the NOGG and NOF Guidelines on the Indication of Bone Mineral Density in Routine Clinical Practice. , 2015, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[31]  J. Kanis,et al.  Intervention Thresholds and the Diagnosis of Osteoporosis , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[32]  J. Kanis,et al.  FRAX and the effect of teriparatide on vertebral and non-vertebral fracture , 2015, Osteoporosis International.

[33]  J. Kanis,et al.  Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX , 2015, Osteoporosis International.

[34]  C. Cooper,et al.  FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.

[35]  D. Mellström,et al.  Is the Swedish FRAX model appropriate for Swedish immigrants? , 2015, Osteoporosis International.

[36]  J. Kanis,et al.  Adjusting Fracture Probability by Trabecular Bone Score , 2015, Calcified Tissue International.

[37]  M. Cowie.  National Institute for Health and Care Excellence. , 2015, European heart journal.

[38]  J. Kanis,et al.  Estimated Lean Mass and Fat Mass Differentially Affect Femoral Bone Density and Strength Index but Are Not FRAX Independent Risk Factors for Fracture , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  A. LaCroix,et al.  Impact of Femoral Neck and Lumbar Spine BMD Discordances on FRAX Probabilities in Women: A Meta-analysis of International Cohorts , 2014, Calcified Tissue International.

[40]  J. Kanis,et al.  Lumbar spine texture enhances 10-year fracture probability assessment , 2014, Osteoporosis International.

[41]  J. Cauley,et al.  Geographic and ethnic disparities in osteoporotic fractures , 2014, Nature Reviews Endocrinology.

[42]  C. Cooper,et al.  Challenges for the Development of Bone-Forming Agents in Europe , 2014, Calcified Tissue International.

[43]  C. Cooper,et al.  Worldwide uptake of FRAX , 2014, Archives of Osteoporosis.

[44]  E. M. Lewiecki,et al.  Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[45]  J. Kanis,et al.  Incidence of Hip Fracture in Romania and the Development of a Romanian FRAX Model , 2013, Calcified Tissue International.

[46]  J. Kanis,et al.  FRAX provides robust fracture prediction regardless of socioeconomic status , 2013, Osteoporosis International.

[47]  Naoto Endo,et al.  Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary , 2012, Archives of Osteoporosis.

[48]  J. Kanis,et al.  Type 2 diabetes and bone , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[49]  J. Kanis,et al.  Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  J. Kanis,et al.  Does osteoporosis therapy invalidate FRAX for fracture prediction? , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  Carol Coupland,et al.  Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study , 2012, BMJ : British Medical Journal.

[52]  C. Cooper,et al.  A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.

[53]  C. Cooper,et al.  A systematic review of hip fracture incidence and probability of fracture worldwide , 2012, Osteoporosis International.

[54]  J. Compston,et al.  A comparison of case-finding strategies in the UK for the management of hip fractures , 2012, Osteoporosis International.

[55]  R. Rizzoli,et al.  Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland , 2012, Osteoporosis International.

[56]  J. Kanis,et al.  FRAX® with and without Bone Mineral Density , 2011, Calcified Tissue International.

[57]  S. Boonen,et al.  Official Positions for FRAX® clinical regarding falls and frailty: can falls and frailty be used in FRAX®? From Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. , 2011, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[58]  J. Kanis,et al.  High fracture probability with FRAX® usually indicates densitometric osteoporosis: implications for clinical practice , 2011, Osteoporosis International.

[59]  W. Leslie,et al.  Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos , 2011, Osteoporosis International.

[60]  J. Kanis,et al.  Spine–hip discordance and fracture risk assessment: a physician-friendly FRAX enhancement , 2011, Osteoporosis International.

[61]  J. Kanis,et al.  A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX® , 2011, Osteoporosis International.

[62]  J. Kanis,et al.  Guidance for the adjustment of FRAX according to the dose of glucocorticoids , 2011, Osteoporosis International.

[63]  Eugene McCloskey,et al.  Independent clinical validation of a Canadian FRAX tool: Fracture prediction and model calibration , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[64]  J. Kanis,et al.  A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. , 2010, Bone.

[65]  W. Leslie,et al.  Time since prior fracture is a risk modifier for 10‐year osteoporotic fractures , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[66]  Carol Coupland,et al.  Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores , 2009, BMJ : British Medical Journal.

[67]  J. Kanis,et al.  Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. , 2009, Bone.

[68]  O. Johnell,et al.  BMD, clinical risk factors and their combination for hip fracture prevention , 2009, Osteoporosis International.

[69]  C. Cooper,et al.  Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. , 2009, Maturitas.

[70]  J. Kanis,et al.  Ten-year fracture probability identifies women who will benefit from clodronate therapy—additional results from a double-blind, placebo-controlled randomised study , 2009, Osteoporosis International.

[71]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[72]  J. Kanis,et al.  Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK , 2008, Osteoporosis International.

[73]  B. Dawson-Hughes.  A revised clinician's guide to the prevention and treatment of osteoporosis. , 2008, The Journal of clinical endocrinology and metabolism.

[74]  N. D. Nguyen,et al.  Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks , 2008, Osteoporosis International.

[75]  L. Melton,et al.  A reference standard for the description of osteoporosis. , 2008, Bone.

[76]  L. Melton,et al.  Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA , 2008, Osteoporosis International.

[77]  C. Cooper,et al.  European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.

[78]  C. Cooper,et al.  The cost-effectiveness of alendronate in the management of osteoporosis. , 2008, Bone.

[79]  L. Melton,et al.  Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.

[80]  O. Johnell,et al.  FRAX™ and the assessment of fracture probability in men and women from the UK , 2008, Osteoporosis International.

[81]  G. Anderson,et al.  Predicting risk of breast cancer in postmenopausal women by hormone receptor status. , 2007, Journal of the National Cancer Institute.

[82]  S. Jamal,et al.  Low bone mineral density and fracture burden in postmenopausal women , 2007, Canadian Medical Association Journal.

[83]  J Bamford,et al.  Current practice, accuracy, effectiveness and cost-effectiveness of the school entry hearing screen. , 2007, Health technology assessment.

[84]  Mark Stevenson,et al.  Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. , 2007, Health technology assessment.

[85]  Jacques P. Brown,et al.  The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women , 2007, Osteoporosis International.

[86]  O. Johnell,et al.  The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry , 2005, Osteoporosis International.

[87]  J. Kanis,et al.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Synopsis of a WHO report , 1994, Osteoporosis International.

[88]  C. Cooper,et al.  Guidelines for diagnosis and management of osteoporosis , 2005, Osteoporosis International.

[89]  Niklas Zethraeus,et al.  Assessment of fracture risk , 2005, Osteoporosis International.

[90]  O. Johnell,et al.  Optimization of BMD Measurements to Identify High Risk Groups for Treatment—A Test Analysis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[91]  O. Johnell,et al.  Fracture risk following an osteoporotic fracture , 2004, Osteoporosis International.

[92]  O. Johnell,et al.  Acute and Long-Term Increase in Fracture Risk after Hospitalization for Vertebral Fracture , 2001, Osteoporosis International.

[93]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.

[94]  O Johnell,et al.  Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. , 2000, Bone.

[95]  N. Ghannam,et al.  Book review: Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. , 1994, Annals of Saudi medicine.